✦ LIBER ✦

Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for Glioblastoma

✍ Scribed by Martin Kocher; Peter Frommolt; Sigrid Klara Borberg; Ursula Rühl; Maria Steingräber; Markus Niewald; Susanne Staar; Martin Stuschke; Gerd Becker; Arnt-René Fischedick; Klaus Herfarth; Hermann Grauthoff; Rolf-Peter Müller

Book ID: 105776648
Publisher: Springer
Year: 2008
Tongue: German
Weight: 302 KB
Volume: 184
Category: Article
ISSN: 0179-7158
DOI: 10.1007/s00066-008-1897-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiotherapy followed by adjuvant temozo

Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase

✍ Il Han Kim; Chul-Kee Park; Dae Seog Heo; Chae-Yong Kim; Chang Hun Rhee; Do-Hyun 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 288 KB

A retrospective study of the safety of B

A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients

✍ Edward Pan; Susan B. Mitchell; Jerry S. Tsai 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 188 KB

A pilot study of primary temozolomide ch

A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma

✍ Marc C. Chamberlain; Lisa Chalmers 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 113 KB

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population

✍ Carol Alliot 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

✍ Olivier-L. Chinot; Maryline Barrie; Elisabeth Frauger; Henry Dufour; Dominique F 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND Currently, the survival of patients age > 70 years with glioblastoma multiforme (GBM) ranges from 4 months to 6 months, although radiotherapy and/or chemotherapy may prolong survival in certain subgroups. Temozolomide is an oral chemotherapeutic agent with efficacy agains

Can we afford to add chemotherapy to rad

Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death

✍ Jean-Blaise Wasserfallen; Sandrine Ostermann; Alessia Pica; René-Olivier Miriman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB